Related Experiment Video
Updated: Jul 18, 2026
03:55
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
Which thyroid cancer patients need periodic stimulation tests?
Paolo Zanotti-Fregonara1, Alexandre Khoury, Françoise Duron
1Service de Médecine Nucléaire, Hôpital Saint-Antoine, 184, rue du Faubourg Saint-Antoine, 75571, Paris cedex 12, France.
European Journal of Nuclear Medicine and Molecular Imaging
|November 16, 2006
Summary
Thyroid cancer follow-up is crucial. Recombinant human thyroid stimulating hormone (rhTSH) stimulation is beneficial for high-risk patients but unnecessary for low-risk stage I thyroid cancer patients with negative initial tests.
Area of Science:
- Endocrinology
- Oncology
- Nuclear Medicine
Background:
- Thyroid cancer recurrences necessitate long-term patient monitoring.
- Risk stratification is key for determining appropriate follow-up strategies after radioactive iodine (131I) ablation.
Purpose of the Study:
- To evaluate the utility of recombinant human thyroid stimulating hormone (rhTSH) stimulation tests in thyroid cancer patients.
- To assess the yield of rhTSH stimulation based on initial risk stratification and first follow-up test results.
Main Methods:
- A cohort of 129 thyroid cancer patients underwent rhTSH stimulation testing.
- Patients were categorized into three groups based on UICC/TNM staging and initial follow-up results (negative or positive).
- Initial follow-up included thyroglobulin (Tg) measurement after hormone withdrawal and 131I diagnostic whole-body scan.
Main Results:
- In Stage I patients with negative initial follow-up (n=75), rhTSH stimulation yielded no evidence of recurrence.
- In Stage I patients with positive initial follow-up (n=19), rhTSH stimulation detected residual disease in some, but without signs of progression.
- In higher-risk Stage II-IV patients (n=35), 14% showed positive rhTSH tests, suggesting disease progression in at least two cases.
Conclusions:
- Initial follow-up testing is critical for prognostication in thyroid cancer patients post-131I ablation.
- Low-risk Stage I patients with undetectable Tg and negative 131I scans after 1 year have a very low recurrence risk and do not need further rhTSH stimulation.
- Periodic rhTSH stimulation is valuable for monitoring higher-risk thyroid cancer patients.
Related Concept Videos
01:25Hyperthyroidism I: Introduction
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
01:23The Thyroid Gland
The thyroid gland is a small, butterfly-shaped gland located in the neck and covers the anterior surface of the trachea. The gland has two lateral lobes connected by a thin tissue mass called the isthmus. Internally, each lobe comprises many small spherical structures known as thyroid follicles, surrounded by a network of blood vessels.
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
01:20Synthesis and Regulation of Thyroid Hormones
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
01:23Hypothyroidism II: Pathophysiology
Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
01:24Graves Disease II: Pathophysiology
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...